Sanofi-Aventis In Talks With Pfizer And P&G About Exubera, Actonel Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Change-in-control triggers discussion about future of Aventis partnerships. Sanofi notes that there is a defined timeline for negotiations, but the company is not making any details public.
You may also be interested in...
Exubera Partnership In Doubt: Pfizer, Sanofi In Litigation Over Inhaled Insulin
Pfizer is seeking to enforce "change-in-control" provisions in the Exubera co-marketing agreement. Sanofi-Aventis says it "has no idea" if Pfizer's goal is to buy out the partnership or force a sale to Sanofi.
Exubera Partnership In Doubt: Pfizer, Sanofi In Litigation Over Inhaled Insulin
Pfizer is seeking to enforce "change-in-control" provisions in the Exubera co-marketing agreement. Sanofi-Aventis says it "has no idea" if Pfizer's goal is to buy out the partnership or force a sale to Sanofi.
Sanofi-Aventis, P&G To Continue Actonel Collaboration
The companies’ new agreement covers R&D and commercial efforts supporting the osteoporosis therapy, Sanofi-Aventis says. Procter & Gamble also will co-promote risedronate in “additional territories.”